Human Anti-KDR Recombinant Antibody (TAB-0298CL) (CAT#: TAB-0298CL)

• Host Species
• Human

• Type
• Human IgG

• Specificity
• Human VEGFR

• Species Reactivity
• Human, Mouse, Rat

• Applications
• WB, FC, ELISA, Inhib, Neut, FuncS

• Related Disease
• Colon Cancer, Lung Cancer,

• Purity
• >95% as determined by SDS-PAGE

• Concentration
• See the COA

• Buffer
• PBS

• Preservative
• No preservatives

• Storage
• Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

• Application Notes
• Western Blot revealed that TAB-0298CL had inhibitory effect on the phosphorylation of ERK in primary cultured HUVEC cells. Flow Cytometry revealed that TAB-0298CL was strongly bound to endogenous human KDR, which was expressed on the surface of living HUVEC cells. The KDR affinity of the antibody was analyzed in ELISA. After adding the TAB-0298CL, the proliferation of the HUVEC cells treated with VEGF was reduced in an antibody concentration-dependent manner. TAB-0298CL had inhibitory effect on the phosphorylation of KDR and the migration of HUVEC cells induced by VEGF. TAB-0298CL had an angiogenesis inhibitory effect in vivo (rat), and anti-cancer effect in cancer xenograft animal models.

• Alternative Names
• KDR; kinase insert domain receptor; FLK1; CD309; VEGFR; VEGFR2; vascular endothelial growth factor receptor 2; soluble VEGFR2; fetal liver kinase 1; fetal liver kinase-1; protein-tyrosine kinase receptor Flk-1; tyrosine kinase growth factor receptor; kinase insert domain receptor (a type III receptor tyrosine kinase);

• Gene ID
• 3791

• UniProt ID
• A0A024RD88

• Long Name
• Kinase insert domain receptor

Isotype Control

• MRO-A1587-YJ
• Human IgG Isotype control, Polyclonal

Secondary Antibody

• 2ND-024CQ
• Goat Anti-Human IgG (H&L) Antibody

• 2ND-025CQ
• Rabbit Anti-Human IgG (H&L) Antibody

Recommended Dilution Buffer

• MRO-0253YJ
• Reconstitution Buffer PBS